Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.aspiradiagnostics.com | |
Market Cap | 43.85 Cr. | |
Enterprise Value(EV) | 43.78 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -1.21 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-09 |
Industry PE | 61.75 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 11.00 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 3.87 | Calculated using Price: 42.60 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.03 Cr. | 10,293,000 Shares |
FaceValue | 10 | |
About Aspira Pathlab & Diagnostics Ltd. | ||
The Company is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. |
1 Day |
|
-0.70% |
1 Week |
|
+12.11% |
1 Month |
|
+17.81% |
3 Month |
|
+3.00% |
6 Month |
|
+32.79% |
1 Year |
|
+0.59% |
2 Year |
|
-49.79% |
5 Year |
|
+127.81% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 1.10 | 0.76 | -57.04 | -178.61 | -187.57 | -94.32 | 22.80 | 42.26 | -0.69 | |
Return on Capital Employed (%) | 3.95 | 1.78 | -25.35 | -38.38 | -34.50 | -26.30 | 21.52 | 41.63 | 2.40 | |
Return on Assets (%) | 1.05 | 0.54 | -25.76 | -40.76 | -37.93 | -29.11 | 10.58 | 29.82 | -0.50 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 4 | 4 | 6 | 0 | 5 | 4 | 8 | 13 | 13 | 11 | |
Non Curr. Liab. | 3 | 11 | 5 | 5 | 1 | 4 | 3 | 3 | |||
Curr. Liab. | 0 | 3 | 6 | 2 | 4 | 5 | 2 | 2 | 2 | 2 | |
Minority Int. | |||||||||||
Equity & Liab. | 4 | 6 | 15 | 13 | 15 | 14 | 12 | 18 | 17 | 16 | |
Non Curr. Assets | 1 | 11 | 11 | 13 | 11 | 8 | 11 | 11 | 11 | ||
Curr. Assets | 4 | 6 | 4 | 2 | 2 | 3 | 4 | 7 | 6 | 5 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 4 | 6 | 15 | 13 | 15 | 14 | 12 | 18 | 17 | 16 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 1 | 4 | 8 | 8 | 15 | 20 | 14 | 14 | |||
Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Total Income | 0 | 0 | 1 | 5 | 8 | 9 | 15 | 20 | 15 | 14 | |
Total Expenditure | 0 | 0 | -3 | -8 | -11 | -10 | -12 | -13 | -13 | -13 | |
PBIDT | 0 | 0 | -2 | -4 | -3 | -2 | 4 | 6 | 2 | 1 | |
Interest | 0 | 0 | 0 | -1 | -1 | -1 | -1 | 0 | 0 | 0 | |
Depreciation | 0 | -1 | -1 | -2 | -1 | -2 | -2 | -2 | |||
Taxation | 0 | 0 | 0 | ||||||||
Exceptional Items | |||||||||||
PAT | 0 | 0 | -3 | -6 | -5 | -4 | 1 | 4 | 0 | -1 | |
Adjusted EPS | 0 | 0 | -5 | -11 | -6 | -5 | 1 | 4 | 0 | -1 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | 0 | -1 | -5 | -3 | -2 | 6 | 2 | 0 | ||
Cash Fr. Inv. | 0 | 0 | 0 | -10 | -1 | -2 | 0 | 0 | -1 | 0 | |
Cash Fr. Finan. | 3 | 3 | 9 | 7 | 3 | 1 | -2 | -1 | -1 | ||
Net Change | 0 | 3 | 2 | -3 | 1 | -2 | 0 | 3 | 0 | -1 | |
Cash & Cash Eqvt | 0 | 3 | 5 | 3 | 0 | -2 | -2 | 1 | 1 | 1 |
Mon, 13 Nov 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Advertisement for Unaudited Financial Results for the quarter and the half year ended September 30 2023 |
Sat, 11 Nov 2023
Board Meeting Outcome for Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Financial Results for the Second Quarter and Half Year Ended 30th September 2023 duly approved by the Audit Committee and Board Meeting in its meeting held on November 11 2023 |
Sat, 28 Oct 2023
Board Meeting Intimation for The Board Meeting To Be Held On Saturday November 11 2023 To Consider And Approve Unaudited Financial Results For The Quarter And Half Year Ended September 30 2023 Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2023 inter alia to consider and approve Standalone Unaudited Financial Results for the quarter and half year ended as on September 30 2023 |
Wed, 29 Nov 2023 |
|
|
|
|
|